Literature DB >> 30685089

Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.

Keith S Abayasiriwardana1, Michael K Wood1, Cecilia M Prêle2, Kimberly A Birnie3, Bruce W Robinson4, Geoffrey J Laurent2, Robin J McAnulty1, Steven E Mutsaers5.   

Abstract

Malignant mesothelioma is an aggressive fibrous tumor, predominantly of the pleura, with a very poor prognosis. Cell-matrix interactions are recognized important determinants of tumor growth and invasiveness but the role of the extracellular matrix in mesothelioma is unknown. Mesothelioma cells synthesize collagen as well as transforming growth factor-beta (TGF-β), a key regulator of collagen production. This study examined the effect of inhibiting collagen production on mesothelioma cell proliferation in vitro and tumor growth in vivo. Collagen production by mesothelioma cells was inhibited by incubating cells in vitro with the proline analogue thiaproline (thiazolidine-4-carboxylic acid) or by oral administration of thiaproline in a murine tumor model. Cell cytotoxicity was measured using neutral red uptake and lactate dehydrogenase assays. Proliferation was measured by tritiated thymidine incorporation, and inflammatory cell influx, proliferation, apoptosis and angiogenesis in tumors examined by immunohistochemical labelling. Tumor size was determined by tumor weight and collagen production was measured by HPLC. Thiaproline at non-toxic doses significantly reduced basal and TGF-β-induced collagen production by over 50% and cell proliferation by over 65%. In vivo thiaproline administration inhibited tumor growth at 10 days, decreasing the median tumor weight by 80%. The mean concentration of collagen was 50% lower in the thiaproline-treated tumors compared with the controls. There were no significant differences in vasculature or inflammatory cell infiltration but apoptosis was increased in thiaproline treated tumors at day 10. In conclusion, these observations strongly support a role for collagen in mesothelioma growth and establish the potential for inhibitors of collagen synthesis in mesothelioma treatment.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal models; Anti-neoplastic agents; Cell proliferation; Malignant mesothelioma; Protein synthesis inhibitors

Mesh:

Substances:

Year:  2019        PMID: 30685089     DOI: 10.1016/j.bbrc.2019.01.057

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

Review 1.  Fibrosis in Mesothelioma: Potential Role of Lysyl Oxidases.

Authors:  Lara Perryman; Steven G Gray
Journal:  Cancers (Basel)       Date:  2022-02-15       Impact factor: 6.639

Review 2.  Strategies for Efficient Targeting of Tumor Collagen for Cancer Therapy.

Authors:  Silvia Baldari; Francesca Di Modugno; Paola Nisticò; Gabriele Toietta
Journal:  Cancers (Basel)       Date:  2022-09-27       Impact factor: 6.575

Review 3.  Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma.

Authors:  Francesca Napoli; Angela Listì; Vanessa Zambelli; Gianluca Witel; Paolo Bironzo; Mauro Papotti; Marco Volante; Giorgio Scagliotti; Luisella Righi
Journal:  Cancers (Basel)       Date:  2021-05-24       Impact factor: 6.639

Review 4.  Mouse models for mesothelioma drug discovery and development.

Authors:  Kenneth P Seastedt; Nathanael Pruett; Chuong D Hoang
Journal:  Expert Opin Drug Discov       Date:  2020-12-31       Impact factor: 7.050

5.  Gene Expression Analysis of Biphasic Pleural Mesothelioma: New Potential Diagnostic and Prognostic Markers.

Authors:  Rossella Bruno; Anello Marcello Poma; Greta Alì; Claudia Distefano; Agnese Proietti; Antonio Chella; Marco Lucchi; Franca Melfi; Renato Franco; Gabriella Fontanini
Journal:  Diagnostics (Basel)       Date:  2022-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.